The Effect of the DASH Diet on Clinical and Metabolic Parameters in Children With MASLD
NCT07480811 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88
Last updated 2026-03-18
Summary
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in childhood is becoming increasingly prevalent, paralleling the rise in obesity rates, and has become the most common chronic liver disease in the pediatric population. MASLD is associated with metabolic mechanisms such as insulin resistance, dyslipidemia, oxidative stress, and inflammation, and can progress to serious complications like steatohepatitis, fibrosis, and cirrhosis in later stages. Currently, pharmacological treatments for managing MASLD are limited, and lifestyle modifications, particularly dietary interventions, stand out as the primary approach for preventing and treating the disease. In this context, the composition of macro and micronutrients plays a critical role in the development and progression of hepatic steatosis.
Within this framework, the Dietary Approaches to Stop Hypertension (DASH) diet is a balanced eating pattern that encourages the consumption of vegetables, fruits, whole grains, legumes, low-fat dairy products, fish, poultry, and healthy fat sources, while limiting sodium, saturated fat, sugary foods, and processed meat products. Similar to the Mediterranean diet, the DASH diet is a promising approach for conditions like metabolic syndrome and MASLD due to its anti-inflammatory potential, its reducing effect on oxidative stress, and its properties that enhance insulin sensitivity. Furthermore, thanks to its high fiber content, it contributes to balancing the gut microbiota and supports the production of short-chain fatty acids (SCFAs), which in turn have positive effects on liver and metabolic health.
Evaluated in terms of fat intake, the DASH diet's emphasis on foods rich in n-3 fatty acids (such as fish and walnuts) provides an anti-inflammatory effect, while limiting saturated and trans fats offers an important strategy for reducing hepatic fat accumulation. Additionally, restricting the consumption of added sugars and fructose may be effective in preventing hepatic steatosis by suppressing lipogenesis processes.
In light of all these scientific findings, considering the impact of dietary patterns on the development and progression of MASLD, appropriately structuring the diet is critically important for protecting liver health in children. Accordingly, an anti-inflammatory, antioxidant, and metabolically balanced DASH dietary model is considered an effective and applicable approach in the management of pediatric MASLD.
Within the scope of this study, the effects of implementing the DASH diet in children with MASLD on clinical and metabolic parameters such as liver enzymes, degree of hepatic steatosis, insulin resistance, lipid profile, and inflammatory markers will be evaluated compared to a control group. Additionally, by examining the relationships between these parameters and quality of life as well as dietary adherence, the potential therapeutic role of the DASH diet in the management of pediatric MASLD will be elucidated.
Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
- OTHER
-
DASH Diet
The DASH diet is structured with a macronutrient distribution of 50-55% carbohydrates, 16-18% protein, and 27-30% fat. The diet plan recommends high intake of fruits, vegetables, low-fat dairy products, oilseeds, legumes, and whole grains, as well as low intake of sodium, sugary foods, and red and processed meats.
- OTHER
-
Standart Diet
The standard diet is planned so that 45-60% of energy comes from carbohydrates, 25-35% from fats, and 15-20% from proteins. The standard diet is based on the healthy eating recommendations for children in the 2022 Turkish Nutrition Guide (TÜBER). Unlike the DASH diet, the standard diet allows the consumption of refined grains, full-fat milk and meat products, and simple sugars not exceeding 10% of energy.
- OTHER
-
Physical Activity
The home-based exercise program aims to increase physical activity. The exercise program is planned as 30 minutes x 5 days a week, under parental supervision or with parental guidance. Participants will be instructed to begin their workout with 10 minutes of warm-up exercises (push-ups, sit-ups, reverse sit-ups, squats, aerial cycling, stretching), continue with 15 minutes of aerobic activities (jump rope, step aerobics, dancing, throwing a ball against a wall, running up and down stairs), and conclude with 5 minutes of cool-down exercises (stretching).
Sponsors & Collaborators
-
Antalya Training and Research Hospital
lead OTHER_GOV
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 11 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-05
- Primary Completion
- 2026-10-30
- Completion
- 2026-12-30
More Related Trials
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
NCT06138821 ·Status: RECRUITING ·Phase: NA
-
Chrononutrition/ Chronotoxicity Intervention in People With Metabolic-associated Steatotic Liver Disease.
NCT06705868 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity
NCT07378072 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
NCT07313007 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Hepatic Elastography-Enhanced Lifestyle Modification in MASLD
NCT06826807 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT05395481 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
NCT05065593 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database
NCT06741111 ·Status: COMPLETED
-
Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in NAFLD Children
NCT05073588 ·Status: COMPLETED ·Phase: NA
-
Mastiha Treatment for Obese With NAFLD Diagnosis
NCT03135873 ·Status: COMPLETED ·Phase: NA
-
Nonalcoholic Steatohepatitis in Chinese Children
NCT03190538 ·Status: RECRUITING
-
DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD
NCT07249112 ·Status: RECRUITING ·Phase: NA
-
Study on Risk Factors and Prognosis of MASLD
NCT07433205 ·Status: COMPLETED
-
Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study
NCT07188220 ·Status: RECRUITING
-
Advanced Fibrosis Detection for MASLD in Primary Care
NCT07159386 ·Status: RECRUITING ·Phase: NA
-
NAFLD and Liver Fibrosis in Obese Adolescents
NCT04561804 ·Status: COMPLETED
-
Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease
NCT07242222 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07013916 ·Status: RECRUITING ·Phase: NA
-
Benefits of Trimetazidine in MASLD Patients
NCT06140953 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Lyophilized Cornus Mas L. on Anthropometric and Biochemical Parameters in Metabolic Associated Fatty Liver Disease Patients
NCT05546450 ·Status: COMPLETED ·Phase: NA
-
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
NCT04454463 ·Status: COMPLETED
-
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
NCT06482112 ·Status: COMPLETED ·Phase: PHASE2
-
Testing a Multilevel, Culturally Appropriate Lifestyle Intervention For Hispanic Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
NCT07199491 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Ketogenic Diet in MASLD-related cACLD
NCT06537466 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD
NCT06352177 ·Status: WITHDRAWN ·Phase: NA